Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Epertinib||S-222611|S222611|S222611||EGFR Inhibitor (Pan) 46 HER2 Inhibitor 23||Epertinib (S-222611) is a dual inhibitor of EGFR and ERBB2 (HER2), leading to decreased kinase activity and potentially inhibiting growth of tumors expressing EGFR or ERBB2 (HER2) (PMID: 24837299, PMID: 30196106, PMID: 31892325).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 over exp||gastroesophageal junction adenocarcinoma||sensitive||Epertinib||Phase I||Actionable||In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient over expressing ERBB2 (HER2) and a partial response in a gastric cancer patient also over expressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).||detail...|
|ERBB2 positive||Advanced Solid Tumor||predicted - sensitive||Epertinib||Phase I||Actionable||In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).||detail... 25434923|
|ERBB2 over exp||stomach cancer||sensitive||Epertinib||Phase I||Actionable||In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient overexpressing ERBB2 (HER2) and a partial response in a gastric cancer patient also overexpressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|